FINVIZ

Viant's Q3 Test: Can Contribution Growth And Margins Offset A Slower Revenue Climb?

The Street expects non-GAAP earnings of $0.18 per share on revenue of $109.2 million. That revenue figure sits just above the ...
FINVIZ*Elite

Boeing and Icelease Sign Agreement for up to Three 767-300 Boeing Converted Freighters

Agreement covers conversion of one 767-300BCF aircraft and secures options for two more PLANO, Texas, Nov. 2, 2026 ...
FINVIZ

Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed ...

Stockholders may obtain copies of the definitive Proxy Statement/Prospectus and other documents filed with the SEC, without charge, at the SEC's website at www.sec.gov or by directing a request to ...
FINVIZ

Valaris Reports Third Quarter 2026 Results

Valaris Needs A Sequential Earnings Rebound To Justify Its Rally Toward Range Highs VAL Earnings Whispers ...
FINVIZ

Ethos Crushes Q3 Estimates And Raises Guidance Again, But Third-Party Mix Shift Keeps Compressing Margins

Ethos Technologies (NASDAQ: LIFE) delivered another blowout quarter, reporting third-quarter non-GAAP earnings of $0.49 per share on revenue of $235.22 million. That beat the $0.37 consensus by 25.6% ...
FINVIZ

Empire State Realty Trust Achieves Highest GRESB Management Score for All Companies in the Americas for Second Consecutive Year, and Top 5-Star Rating

Empire State Realty Trust, Inc. (NYSE: ESRT) announced today that it was named Regional Sector Leader and achieved the highest management score for all 529 ranked companies in the Americas. The ...
FINVIZ

Lightbridge's Loss Widens 43.8% As INL Pilot Factory Path Turns A Testing Story Into A Commercialization Bet With A Larger Capital Bill

Lightbridge (NASDAQ: LTBR) reported a third-quarter loss of $0.23 per share, a 43.8% deterioration from the $0.16 loss a year earlier. As a pre-revenue nuclear fuel developer with no consensus ...
FINVIZ

Bioventus Matches On EPS But Cuts Its Revenue Outlook As Debt Paydown, Not Operations, Drives Earnings Growth

Earnings Whispers. Bioventus delivered an in-line bottom line and a disappointing top line, and the guidance revision matters more than either. Adjusted EPS of $0.17 matched conse ...
FINVIZ

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement - FINVIZ.com

Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 ---- Rhythm ...
FINVIZ

Coherus Needs Loctorsi Growth And A Udenica Milestone To Steady A Sub-Dollar Stock

Coherus BioSciences heads into its third-quarter report with an odd disconnect. Three months ago, management delivered its most confident call in a year, finally putting a number on Loctorsi with full ...
FINVIZ

V2X Beats Consensus But Misses The Whisper As Growth Slows, Even With Another Guidance Raise And An Early 2027 Growth Call

V2X (NYSE: VVX) delivered a third quarter that looks better against consensus than against the bar investors actually set. Adjusted EPS of $1.64 topped the $1.54 consensus but fell 2.4% short of the ...
FINVIZ

Oracle Announces Pricing of $20 Billion of Common Stock and Senior Notes

The net proceeds from the common stock offering will be approximately $9.9 billion, after deducting the underwriting discounts and Oracle's estimated offering expenses. The net proceeds from the notes ...